Published on 14/03/2017 5:03:13 PM | Source: Angel Broking Pvt Ltd

USFDA to Lift Import Alert Regulator to permit supply of products from Mohali: Angel

Posted in Expert Views | #Pharma Sector #Sun Pharmaceuticals Industries Ltd #Shasun Pharmaceuticals Ltd. #Angel Broking Pvt Ltd #Sarabjit Kour Nangra


Below is the views Sun Pharmaceutical Industries Ltd By Ms. Sarabjit Kour Nangra (VP Research- Pharma, Angel Broking Pvt Ltd):

 

“Sun Pharmaceutical was informed by the US FDA, that it will lift the Import Alert imposed on the Mohali (Punjab) manufacturing facility and remove the facility from the Official Action Initiated (OAI) status. This proposed action will clear the path for Sun Pharmaceutical to supply approved products from the Mohali facility to the US market, subject to normal US FDA regulatory requirements. The Mohali facility was inherited by Sun Pharmaceutical as part of its acquisition of Ranbaxy Laboratories Ltd. in 2015. The US FDA had taken action against the Mohali facility in 2013 when it ordered the facility to be fully subject to Ranbaxy’s Consent Decree of Permanent Injunction. Certain conditions of the consent decree will continue to be applicable to the Mohali facility. This will pave way for better growth for the company in US and improvement in asset utilisations and hence return ratios in long run. We maintain our BUY rating with a price target of INR 847.”

 

 

Click here to open demat account    

 

For More Angel Broking Pvt Ltd Disclaimer   http://www.angelsecurities.in/disclaimer.aspx     

 

Above views are of the author and not of the website kindly read disclaimer